Clinical trials: in Thailand
Invasive Mold Infections
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
The purpose of this study is to evaluate the efficacy and safety of fosmanogepix (administered IV or oral) for the treatment of adult patients with invasive mold infections.
- Trial name
- NCT06925321
- Testing
- Fosmanogepix IV infusion, Standard of care antifungal therapy, Fosmanogepix oral tablet
- Where
- 90 sites in United States, Australia and 13 more
- Volunteers
- 234 people
- Sponsor
- Basilea Pharmaceutica
Lupus Nephritis
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
The purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis
- Trial name
- IRIS (NCT05138133)
- Testing
- Anifrolumab
- Where
- 164 sites in United States, Argentina and 22 more
- Volunteers
- 363 people
- Sponsor
- AstraZeneca
Glycogen Storage Disease Type II, Pompe Disease
Pompe Disease Registry Protocol
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both…
- Trial name
- NCT00231400
- Where
- 282 sites in United States, Argentina and 42 more
- Volunteers
- 2,000 people
- Sponsor
- Genzyme, a Sanofi Company
Focal Segmental Glomerulosclerosis
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
PODOMOUNT-pFSGS This study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT07220083
- Testing
- BI 764198
- Where
- 316 sites in United States, Argentina and 38 more
- Volunteers
- 286 people
- Sponsor
- Boehringer Ingelheim
Non-squamous Non-small Cell Lung Cancer
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with locally…
- Trial name
- NCT06627647
- Testing
- Rilvegostomig, Pembrolizumab, Carboplatin
- Where
- 301 sites in United States, Argentina and 23 more
- Volunteers
- 1,160 people
- Sponsor
- AstraZeneca
Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
The purpose of this study is to provide continued access to anifrolumab to eligible participants who are continuing to derive clinical benefit from treatment at the end of a parent clinical study, as assessed by the Investigator…
- Trial name
- ROSY-S (NCT07691970)
- Testing
- Anifrolumab
- Where
- 153 sites in United States, Argentina and 33 more
- Volunteers
- 1,072 people
- Sponsor
- AstraZeneca
Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves…
- Trial name
- NCT07472517
- Testing
- obrixtamig, atezolizumab, carboplatin
- Where
- 243 sites in United States, Argentina and 40 more
- Volunteers
- 670 people
- Sponsor
- Boehringer Ingelheim
Chronic Inflammatory Demyelinating Polyneuropathy
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
The purpose of this Phase 3 study is to demonstrate the efficacy of claseprubart (DNTH103) as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).
- Trial name
- CAPTIVATE (NCT06858579)
- Testing
- Claseprubart
- Where
- 201 sites in United States, Argentina and 29 more
- Volunteers
- 256 people
- Sponsor
- Dianthus Therapeutics
Nonalcoholic Steatohepatitis
A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
A Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 given by subcutaneous injection in adult participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosis and who are carriers of the PNPLA3 148M…
- Trial name
- FORTUNA (NCT05809934)
- Testing
- AZD2693
- Where
- 163 sites in United States, Argentina and 20 more
- Volunteers
- 220 people
- Sponsor
- AstraZeneca
Advanced or Metastatic Non-small Cell Lung Cancer
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.
- Trial name
- ALTAIR (NCT06996782)
- Testing
- Rilvegostomig, Cisplatin, Carboplatin
- Where
- 103 sites in United States, Belgium and 18 more
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2, Hypertension
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure.
- Conditions
- Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
- Trial name
- NCT07064473
- Testing
- Vicadrostat, Empagliflozin
- Where
- 1,142 sites in United States, Argentina and 49 more
- Volunteers
- 11,800 people
- Sponsor
- Boehringer Ingelheim
Advanced Solid Tumors
A Study of BG-C477 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477 alone and in combination with anticancer agents in participants with selected…
- Trial name
- NCT06596473
- Testing
- BG-C477, Tislelizumab, Chemotherapy
- Where
- 59 sites in United States, Australia and 6 more
- Volunteers
- 310 people
- Sponsor
- BeOne Medicines
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or…
- Trial name
- FIBRONEER™-ON (NCT06238622)
- Testing
- Nerandomilast
- Where
- 375 sites in United States, Argentina and 42 more
- Volunteers
- 1,666 people
- Sponsor
- Boehringer Ingelheim
Head and Neck Squamous Cell Carcinoma
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
This study is open to adults with head and neck cancer. The purpose of this study is to find out whether combining different study medicines makes tumors shrink in people with head and neck cancer.
- Trial name
- NCT06806852
- Testing
- BI 770371, Pembrolizumab, Cetuximab
- Where
- 51 sites in United States, Australia and 20 more
- Volunteers
- 91 people
- Sponsor
- Boehringer Ingelheim
Pyruvate Kinase Deficiency
Pyruvate Kinase Deficiency Global Longitudinal Registry
This study is an observational (ie, noninterventional), longitudinal, multicenter, global registry for patients with pyruvate kinase (PK) deficiency, a rare nonspherocytic hemolytic anemia.
- Trial name
- PEAK Registry (NCT03481738)
- Where
- 52 sites in United States, Canada and 14 more
- Volunteers
- 500 people
- Sponsor
- Agios Pharmaceuticals, Inc.
Bronchiectasis
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
This study is open to adults and adolescents aged 12 to under 18 with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exacerbations).
- Trial name
- NCT06872892
- Testing
- BI 1291583
- Where
- 478 sites in United States, Argentina and 44 more
- Volunteers
- 1,755 people
- Sponsor
- Boehringer Ingelheim
Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
The primary objective of this study was to compare the effect of mitapivat versus placebo on transfusion burden in participants with α- or β-transfusion-dependent thalassemia.
- Trial name
- ENERGIZE-T (NCT04770779)
- Testing
- Mitapivat
- Where
- 75 sites in United States, Brazil and 17 more
- Volunteers
- 258 people
- Sponsor
- Agios Pharmaceuticals, Inc.
Non-Small Cell Lung Cancer
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally…
- Trial name
- TROPION-Lung10 (NCT06357533)
- Testing
- Datopotamab Deruxtecan, Rilvegostomig, Pembrolizumab
- Where
- 290 sites in United States, Australia and 19 more
- Volunteers
- 675 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent…
- Trial name
- ARNASA (NCT05595642)
- Testing
- Astegolimab
- Where
- 348 sites in United States, Argentina and 34 more
- Volunteers
- 1,380 people
- Sponsor
- Hoffmann-La Roche
Pre-Exposure Prophylaxis
Developing mHealth to Promote PrEP Use Among Thai Young Men Who Have Sex With Men
The goal of this study is to develop and pilot test technology-based interventions to promote Pre-exposure Prophylaxis (PrEP) uptake and adherence among Thai young men who have sex with men (YMSM).
- Trial name
- NCT05243030
- Testing
- Motivational Enhancement System for PrEP Uptake and Adherence (MES-PrEP), Motivational Interactive Text Messaging (MTM), Standard PrEP Counseling
- Where
- 3 sites in Thailand
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.